Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Susan De Santi"'
Autor:
Gang Li, Nicola Toschi, Viswanath Devanarayan, Richard Batrla, Tommaso Boccato, Min Cho, Matteo Ferrante, Feride Frech, James E. Galvin, David Henley, Soeren Mattke, Susan De Santi, Harald Hampel
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-11 (2023)
Abstract Background Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and related dementia disorders (ADRD) would facilitate the development of individualized prevention plans. We investi
Externí odkaz:
https://doaj.org/article/2a894fcef61e4e38b26922df4223c0da
Autor:
Ronald C. Petersen, Ana Graf, Chris Brady, Susan De Santi, Hana Florian, Jaren Landen, Mike Pontecorvo, Christopher Randolph, Kaycee M. Sink, Maria C. Carrillo, Christopher J. Weber
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 4, Pp n/a-n/a (2023)
Abstract Alzheimer's disease (AD) staging criteria lack standardized, empirical description. Well‐defined AD staging criteria are an important consideration in protocol design, influencing a more standardized inclusion/exclusion criteria and defini
Externí odkaz:
https://doaj.org/article/3165a19f6e46401bb79c035cd29ef3bd
Autor:
Santiago Bullich, Andre Mueller, Susan De Santi, Norman Koglin, Stephen Krause, June Kaplow, Michio Kanekiyo, Núria Roé-Vellvé, Audrey Perrotin, Aleksandar Jovalekic, David Scott, Michelle Gee, Andrew Stephens, Michael Irizarry
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-13 (2022)
Abstract Background The ability of 18F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer’s disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition using 18F-PI-26
Externí odkaz:
https://doaj.org/article/8e77b5cba44a4f58a7c6388004ac5e5a
Autor:
Santiago Bullich, Núria Roé-Vellvé, Marta Marquié, Susan M. Landau, Henryk Barthel, Victor L. Villemagne, Ángela Sanabria, Juan Pablo Tartari, Oscar Sotolongo-Grau, Vincent Doré, Norman Koglin, Andre Müller, Audrey Perrotin, Aleksandar Jovalekic, Susan De Santi, Lluís Tárraga, Andrew W. Stephens, Christopher C. Rowe, Osama Sabri, John P. Seibyl, Mercè Boada
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-15 (2021)
Abstract Background A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earlies
Externí odkaz:
https://doaj.org/article/6b3f6777c03f4d5e85d5f200936af1eb
Autor:
Santiago Bullich, John Seibyl, Ana M. Catafau, Aleksandar Jovalekic, Norman Koglin, Henryk Barthel, Osama Sabri, Susan De Santi
Publikováno v:
NeuroImage: Clinical, Vol 15, Iss , Pp 325-332 (2017)
Introduction: Standardized uptake value ratios (SUVRs) calculated from cerebral cortical areas can be used to categorize 18F-Florbetaben (FBB) PET scans by applying appropriate cutoffs. The objective of this work was first to generate FBB SUVR cutoff
Externí odkaz:
https://doaj.org/article/82f7828eacec49ea9a63d0c749624dcb
Autor:
Harald Hampel, Rhoda Au, Soeren Mattke, Wiesje M. van der Flier, Paul Aisen, Liana Apostolova, Christopher Chen, Min Cho, Susan De Santi, Peng Gao, Atsushi Iwata, Ricky Kurzman, Andrew J. Saykin, Stefan Teipel, Bruno Vellas, Andrea Vergallo, Huali Wang, Jeffrey Cummings
Publikováno v:
Hampel, H, Au, R, Mattke, S, van der Flier, W M, Aisen, P, Apostolova, L, Chen, C, Cho, M, de Santi, S, Gao, P, Iwata, A, Kurzman, R, Saykin, A J, Teipel, S, Vellas, B, Vergallo, A, Wang, H & Cummings, J 2022, ' Designing the next-generation clinical care pathway for Alzheimer’s disease ', Nature Aging, vol. 2, no. 8, pp. 692-703 . https://doi.org/10.1038/s43587-022-00269-x
Nature aging 2(8), 692-703 (2022). doi:10.1038/s43587-022-00269-x
Nature Aging, 2(8), 692-703. Springer
Nature aging 2(8), 692-703 (2022). doi:10.1038/s43587-022-00269-x
Nature Aging, 2(8), 692-703. Springer
The reconceptualization of Alzheimer’s disease (AD) as a clinical and biological construct has facilitated the development of biomarker-guided, pathway-based targeted therapies, many of which have reached late-stage development with the near-term p
Autor:
Santiago Bullich, Susan De Santi, Norman Koglin, Ludger Dinkelborg, Audrey Perrotin, Kenneth Marek, John Seibyl, Mathias Berndt, Olivier Barret, Andrew W. Stephens, Andre Mueller, Andrea Pfeifer, Heiko Kroth, Gilles Tamagnan, Jennifer Madonia, Caroline Papin
Publikováno v:
Journal of Nuclear Medicine. 61:911-919
18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, 18F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purp
Autor:
Susan De Santi, Audrey Perrotin, John Seibyl, Aleksandar Jovalekic, Christopher C. Rowe, Andre Müller, Vincent Dore, Andrew W. Stephens, Henryk Barthel, Juan Pablo Tartari, Marta Marquié, Lluís Tárraga, Mercè Boada, Oscar Sotolongo-Grau, Osama Sabri, Angela Sanabria, Susan M. Landau, Núria Roé-Vellvé, Norman Koglin, Santiago Bullich, Victor L. Villemagne
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-15 (2021)
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-15 (2021)
Background A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earliest abnorma
Autor:
Henryk Barthel, Santiago Bullich, Ludger Dinkelborg, Vincent Dore, Christopher C. Rowe, Andrew W. Stephens, Victor L. Villemagne, Colin L. Masters, Olivier Salvado, Jurgen Fripp, Susan De Santi, Pierrick Bourgeat, Salamata Konate, Osama Sabri
Publikováno v:
Alzheimer's & Dementia. 15:807-816
Introduction 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burde
Autor:
Santiago, Bullich, Núria, Roé-Vellvé, Marta, Marquié, Susan M, Landau, Henryk, Barthel, Victor L, Villemagne, Ángela, Sanabria, Juan Pablo, Tartari, Oscar, Sotolongo-Grau, Vincent, Doré, Norman, Koglin, Andre, Müller, Audrey, Perrotin, Aleksandar, Jovalekic, Susan, De Santi, Lluís, Tárraga, Andrew W, Stephens, Christopher C, Rowe, Osama, Sabri, John P, Seibyl, Mercè, Boada
Publikováno v:
Alzheimer's Research & Therapy
Background A low amount and extent of Aβ deposition at early stages of Alzheimer’s disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earliest abnorma